News Archive

EPO intends to grant APOSEC patent for treatment of systemic conditions (02 Apr. 2015)

We are pleased to announce that the European Patent Office informed us of its intention to grant our patent application 09795982.9 concerning the treatment of internal conditions with PBMC (Peripheral Blood Mononuclear Cells).

The patent concerning the treatment of internal inflammatory skin conditions with APOSEC has already been granted by the EPO in July 2013, patent number: 2379085

go back to news archive

Latest News

Approval for clinical phase II study in DFU by Austrian health agency



US Patent Office issues Allowance for APOSEC Patent